A Greater Cincinnati biopharma startup that’s developing new interventions for acute and chronic lung diseases – including for very preterm infants and Covid-19 patients – received a key FDA approval last week.
Click here to read the complete story.
Story excerpt provided by Cincinnati Business Courier.
Written by Liz Engel.
Originally published March 31, 2021.